Blueberries Medical Corp. BBM

Company Overview

Blueberries Medical Corp. (CSE: BBM) is a Canadian-based cannabis company focused on the cultivation, processing, and commercialization of medicinal cannabis and cannabis-derived products, primarily in Latin America. The company operates in the pharmaceutical and medical cannabis industries, with an emphasis on low-cost production in Colombia and the development of cannabinoid-based products for domestic and export markets. Its business model has historically centered on leveraging Colombia’s climate and agricultural conditions to produce cannabis biomass and extracts at comparatively lower operating costs than producers in North America and Europe.

The company’s primary revenue drivers have included the cultivation of cannabis flower, extraction activities, and the development of medical cannabis formulations intended for pharmaceutical and wellness applications. Blueberries Medical has positioned itself around vertically integrated cannabis operations, including cultivation infrastructure and extraction capabilities. Public disclosures indicate that the company evolved from a broader cannabis cultivation strategy into a more focused medicinal cannabis platform targeting regulated international markets. Data regarding recent commercial scale and revenue contribution by individual product category is limited in current public disclosures, and some operational details are inconclusive based on available public sources.

Business Operations

Blueberries Medical’s operations have historically been concentrated through its Colombian subsidiaries and licensed cannabis assets. The company has controlled cultivation facilities, greenhouse infrastructure, and extraction operations designed to support cannabinoial extract production and pharmaceutical-grade cannabis derivatives. Its operating model has included cultivation, post-harvest processing, extraction, and formulation activities within Colombia’s regulated medical cannabis framework. The company has also pursued export-oriented opportunities where permitted under international cannabis regulations.

The company’s operational footprint has primarily been centered in Colombia, while maintaining corporate functions in Canada due to its public listing structure. Public filings and investor materials have referenced the importance of Colombian agricultural conditions, lower labor costs, and regulatory licensing as strategic assets. Blueberries Medical has also reported relationships with distribution and pharmaceutical partners intended to support commercialization in Latin America and other international medical cannabis markets. Information regarding active joint ventures, large-scale international distribution agreements, or material operating subsidiaries beyond its Colombian cannabis operations remains limited in recent publicly available disclosures.

Strategic Position & Investments

Blueberries Medical’s strategic direction has focused on becoming a cost-efficient producer of medicinal cannabis products for regulated international markets. The company has emphasized pharmaceutical compliance, cannabinoid extraction capabilities, and export potential from Colombia. Its growth initiatives have historically included expanding cultivation capacity, strengthening extraction infrastructure, and pursuing certifications required for international medical cannabis trade. Management has also highlighted the strategic importance of Colombia’s climate advantages and lower production costs relative to producers operating in colder climates.

The company has invested in cannabis cultivation assets, greenhouse infrastructure, and extraction technologies intended to support pharmaceutical-grade production standards. Public filings have also referenced efforts to participate in emerging international cannabis supply chains, particularly within Latin America and potentially Europe. However, the extent of commercial scale achieved in these markets remains unclear based on available public information. Data regarding recent acquisitions, material portfolio investments, or significant ownership stakes in external cannabis ventures is inconclusive based on available public sources.

Geographic Footprint

Blueberries Medical maintains corporate ties to Canada through its public market presence while conducting core cannabis operations in Colombia. The company’s operational infrastructure and licensed cannabis activities have been primarily concentrated in Colombian cultivation regions suited for year-round agricultural production. Colombia has served as the company’s central production and processing hub due to favorable climate conditions and comparatively lower operating costs.

The company has publicly discussed participation in international medical cannabis markets and export opportunities across Latin America, with broader strategic interest in regulated global cannabis jurisdictions. While the company has identified international expansion opportunities in public disclosures, verified evidence of substantial operational scale across multiple continents remains limited. Current publicly available information primarily supports a Colombia-centered operating footprint with Canadian corporate governance and capital markets exposure.

Leadership & Governance

Blueberries Medical has operated under a Canadian public company governance structure, with leadership overseeing cannabis cultivation, regulatory compliance, capital markets activities, and international business development. The company’s management strategy has emphasized low-cost production, pharmaceutical quality standards, and expansion into regulated medicinal cannabis markets. Leadership communications in public filings and investor materials have consistently focused on leveraging Colombian operational advantages and positioning the company for participation in international cannabis supply chains.

Key executives and directors identified in public disclosures have included:

• Camilo Torres – Chief Executive Officer
• Jorge Vazquez – Chief Financial Officer
• Felipe de la Vega – Director
• Camilo Bernal – Director

Executive composition and board membership may have changed over time, and some leadership information differs across public filings and market databases. Data regarding current executive appointments is inconclusive based on available public sources.